UY35624A - Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington - Google Patents
Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntingtonInfo
- Publication number
- UY35624A UY35624A UY35624A UY35624A UY35624A UY 35624 A UY35624 A UY 35624A UY 35624 A UY35624 A UY 35624A UY 35624 A UY35624 A UY 35624A UY 35624 A UY35624 A UY 35624A
- Authority
- UY
- Uruguay
- Prior art keywords
- disease
- pridopidine
- high dose
- treat huntington
- huntington
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Abstract
Método de tratamiento de un paciente humano que sufre de la enfermedad de Huntington, que comprende administrar periódicamente por vía oral al paciente una composición farmacéutica que comprende pridopidina o una sal farmacéuticamente aceptable de la misma de manera tal que se administren más de 90 mg de pridopidina a dicho paciente por día
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361837928P | 2013-06-21 | 2013-06-21 | |
US201361877832P | 2013-09-13 | 2013-09-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY35624A true UY35624A (es) | 2015-01-30 |
Family
ID=52105289
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY35624A UY35624A (es) | 2013-06-21 | 2014-06-23 | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington |
Country Status (24)
Country | Link |
---|---|
US (1) | US10322119B2 (es) |
EP (1) | EP3010506B1 (es) |
JP (1) | JP2016523862A (es) |
KR (1) | KR102316933B1 (es) |
CN (1) | CN105592848A (es) |
AU (1) | AU2014281414A1 (es) |
BR (1) | BR112015029918A2 (es) |
CA (1) | CA2913781C (es) |
CL (1) | CL2015003690A1 (es) |
DK (1) | DK3010506T3 (es) |
EA (1) | EA201690069A1 (es) |
ES (1) | ES2879631T3 (es) |
HK (1) | HK1221646A1 (es) |
HU (1) | HUE054783T2 (es) |
IL (1) | IL242804B (es) |
MX (1) | MX2015017307A (es) |
PE (2) | PE20160195A1 (es) |
PH (1) | PH12015502691A1 (es) |
PL (1) | PL3010506T3 (es) |
SG (1) | SG11201509729YA (es) |
TW (1) | TW201529069A (es) |
UA (1) | UA122999C2 (es) |
UY (1) | UY35624A (es) |
WO (1) | WO2014205229A1 (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
US20130197031A1 (en) | 2010-09-03 | 2013-08-01 | IVAX International GmbH | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
US9012476B2 (en) | 2011-12-08 | 2015-04-21 | IVAX International GmbH | Hydrobromide salt of pridopidine |
US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
EP3096759B1 (en) * | 2014-01-22 | 2022-04-06 | Prilenia Neurotherapeutics Ltd. | Modified release formulations of pridopidine |
TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
CA2970799A1 (en) | 2014-12-22 | 2016-06-30 | Teva Pharmaceuticals International Gmbh | L-tartrate salt of pridopidine |
US11471449B2 (en) * | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
JP6887952B2 (ja) * | 2015-02-25 | 2021-06-16 | プリレニア ニューロセラピューティクス リミテッド | 認知機能を改善するため、およびアルツハイマー病を治療するためのプリドピジンの使用 |
US20170020854A1 (en) * | 2015-07-22 | 2017-01-26 | Teva Pharmaceuticals International Gmbh | Pridopidine base formulations and their use |
AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
US11738012B2 (en) | 2016-02-24 | 2023-08-29 | Prilenia Neurotherapeutics Ltd. | Treatment of neurodegenerative eye disease using pridopidine |
JP6912574B2 (ja) * | 2016-08-24 | 2021-08-04 | プリレニア ニューロセラピューティクス リミテッド | 機能低下を治療するためのプリドピジンの使用 |
JP7278210B2 (ja) * | 2016-08-24 | 2023-05-19 | プリレニア ニューロセラピューティクス リミテッド | ジストニアを治療するためのプリドピジンの使用 |
CA3036842A1 (en) * | 2016-09-15 | 2018-03-22 | Prilenia Therapeutics Development Ltd. | Use of pridopidine for the treatment of anxiety and depression |
CN109982686A (zh) | 2016-09-16 | 2019-07-05 | 普瑞尼亚医疗发展有限公司 | 普利多匹定用于治疗rett综合征的用途 |
BR112019015000A2 (pt) | 2017-01-20 | 2020-04-07 | Agency Science Tech & Res | uso de pridopidina para o tratamento da síndrome do x frágil |
JP7082186B2 (ja) | 2017-08-14 | 2022-06-07 | プリレニア ニューロセラピューティクス リミテッド | プリドピジンによる筋萎縮性側索硬化症の治療方法 |
CN111278431A (zh) * | 2017-08-30 | 2020-06-12 | 普瑞尼亚神经治疗有限公司 | 普利多匹定的高浓度剂型 |
JP2020533296A (ja) | 2017-09-08 | 2020-11-19 | プリレニア ニューロセラピューティクス リミテッド | 薬物誘発性ジスキネジアを治療するためのプリドピジン |
BR112021024744A2 (pt) * | 2019-06-12 | 2022-03-22 | Prilenia Neurotherapeutics Ltd | Método para melhorar, manter ou reduzir o comprometimento da capacidade funcional e função motora de um paciente humano com doença de huntington |
EP4030993A4 (en) * | 2019-09-17 | 2023-10-25 | F. Hoffmann-La Roche AG | IMPROVEMENTS IN PERSONALIZED HEALTH CARE FOR PATIENTS WITH MOTOR DISORDERS |
WO2022094565A1 (en) * | 2020-10-28 | 2022-05-05 | Buck Institute For Research On Aging | N-propargylglycine: a unique inhibitor of proline dehydrogenase with brain-enhancing mitohormesis properties capable of mitigating neurodegenerative disorders |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
SE9904724D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
WO2005053703A1 (en) | 2003-12-02 | 2005-06-16 | Leslie James Sheldon | Combination therapy for dementia, depression and apathy |
CN101056854B (zh) | 2004-10-13 | 2013-06-05 | Nsab神经研究瑞典公司分公司 | 合成4-(3-甲磺酰基苯基)-1-n-丙基-哌啶的方法 |
EP1815857A1 (en) * | 2006-02-02 | 2007-08-08 | LEK Pharmaceuticals D.D. | A pharmaceutical composition comprising perindopril |
AU2008239841B2 (en) | 2007-04-12 | 2013-07-18 | Teva Pharmaceuticals International Gmbh | N-oxide and/or di-N-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles |
US8669048B2 (en) | 2008-06-24 | 2014-03-11 | Parkinson's Institute | Pluripotent cell lines and methods of use thereof |
US8384755B2 (en) | 2009-08-26 | 2013-02-26 | Intouch Technologies, Inc. | Portable remote presence robot |
US20110206782A1 (en) * | 2010-02-24 | 2011-08-25 | Auspex Pharmaceuticals, Inc. | Piperidine modulators of dopamine receptor |
WO2011107583A1 (en) * | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
US20130197031A1 (en) | 2010-09-03 | 2013-08-01 | IVAX International GmbH | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
JP6189299B2 (ja) | 2011-09-07 | 2017-08-30 | テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハー | プリドピジン塩酸塩の新規な多形形態 |
US9012476B2 (en) * | 2011-12-08 | 2015-04-21 | IVAX International GmbH | Hydrobromide salt of pridopidine |
US9744155B2 (en) | 2012-03-28 | 2017-08-29 | Ixcela, Inc. | IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk |
CN104470585A (zh) | 2012-04-04 | 2015-03-25 | 爱华克斯国际有限公司 | 用于联合疗法的药物组合物 |
US20150209346A1 (en) | 2012-09-27 | 2015-07-30 | Teva Pharmaceutical Industries, Ltd. | Combination of laquinimod and pridopidine for treating neurodegenerative disorders, in particular huntington's disease |
AU2013323133A1 (en) | 2012-09-27 | 2015-05-07 | Teva Pharmaceutical Industries Ltd. | Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular Huntington's disease |
EP3096759B1 (en) | 2014-01-22 | 2022-04-06 | Prilenia Neurotherapeutics Ltd. | Modified release formulations of pridopidine |
TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
CA2970799A1 (en) | 2014-12-22 | 2016-06-30 | Teva Pharmaceuticals International Gmbh | L-tartrate salt of pridopidine |
WO2016138135A1 (en) | 2015-02-25 | 2016-09-01 | Teva Pharmaceuticals International Gmbh | Sigma-1 receptor modulators for treating huntington's disease |
JP6887952B2 (ja) | 2015-02-25 | 2021-06-16 | プリレニア ニューロセラピューティクス リミテッド | 認知機能を改善するため、およびアルツハイマー病を治療するためのプリドピジンの使用 |
US20170020854A1 (en) | 2015-07-22 | 2017-01-26 | Teva Pharmaceuticals International Gmbh | Pridopidine base formulations and their use |
AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
WO2017048457A1 (en) | 2015-09-18 | 2017-03-23 | Teva Pharmaceuticals Industries Ltd. | Combination of laquinimod and pridopidine to treat multiple sclerosis |
JP7278210B2 (ja) | 2016-08-24 | 2023-05-19 | プリレニア ニューロセラピューティクス リミテッド | ジストニアを治療するためのプリドピジンの使用 |
JP6912574B2 (ja) * | 2016-08-24 | 2021-08-04 | プリレニア ニューロセラピューティクス リミテッド | 機能低下を治療するためのプリドピジンの使用 |
CA3036842A1 (en) | 2016-09-15 | 2018-03-22 | Prilenia Therapeutics Development Ltd. | Use of pridopidine for the treatment of anxiety and depression |
CN109982686A (zh) | 2016-09-16 | 2019-07-05 | 普瑞尼亚医疗发展有限公司 | 普利多匹定用于治疗rett综合征的用途 |
WO2018053275A1 (en) | 2016-09-16 | 2018-03-22 | Teva Pharmaceuticals International Gmbh | Use of pridopidine for the treatment of familial dysautonomia |
-
2014
- 2014-06-19 MX MX2015017307A patent/MX2015017307A/es unknown
- 2014-06-19 PE PE2015002618A patent/PE20160195A1/es not_active Application Discontinuation
- 2014-06-19 WO PCT/US2014/043204 patent/WO2014205229A1/en active Application Filing
- 2014-06-19 CA CA2913781A patent/CA2913781C/en active Active
- 2014-06-19 PL PL14813621T patent/PL3010506T3/pl unknown
- 2014-06-19 BR BR112015029918A patent/BR112015029918A2/pt not_active Application Discontinuation
- 2014-06-19 UA UAA201600462A patent/UA122999C2/uk unknown
- 2014-06-19 EP EP14813621.1A patent/EP3010506B1/en active Active
- 2014-06-19 AU AU2014281414A patent/AU2014281414A1/en not_active Abandoned
- 2014-06-19 EA EA201690069A patent/EA201690069A1/ru unknown
- 2014-06-19 DK DK14813621.1T patent/DK3010506T3/da active
- 2014-06-19 HU HUE14813621A patent/HUE054783T2/hu unknown
- 2014-06-19 KR KR1020167001531A patent/KR102316933B1/ko active IP Right Grant
- 2014-06-19 US US14/309,111 patent/US10322119B2/en active Active
- 2014-06-19 PE PE2016002253A patent/PE20170302A1/es not_active Application Discontinuation
- 2014-06-19 ES ES14813621T patent/ES2879631T3/es active Active
- 2014-06-19 SG SG11201509729YA patent/SG11201509729YA/en unknown
- 2014-06-19 CN CN201480035525.7A patent/CN105592848A/zh active Pending
- 2014-06-19 JP JP2016521580A patent/JP2016523862A/ja not_active Withdrawn
- 2014-06-20 TW TW103121433A patent/TW201529069A/zh unknown
- 2014-06-23 UY UY35624A patent/UY35624A/es not_active Application Discontinuation
-
2015
- 2015-11-26 IL IL242804A patent/IL242804B/en unknown
- 2015-12-02 PH PH12015502691A patent/PH12015502691A1/en unknown
- 2015-12-21 CL CL2015003690A patent/CL2015003690A1/es unknown
-
2016
- 2016-08-16 HK HK16109788.9A patent/HK1221646A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
PH12015502691A1 (en) | 2016-03-14 |
PE20160195A1 (es) | 2016-05-14 |
US10322119B2 (en) | 2019-06-18 |
SG11201509729YA (en) | 2015-12-30 |
WO2014205229A8 (en) | 2015-04-09 |
HUE054783T2 (hu) | 2021-09-28 |
PL3010506T3 (pl) | 2021-11-02 |
HK1221646A1 (zh) | 2017-06-09 |
CN105592848A (zh) | 2016-05-18 |
AU2014281414A1 (en) | 2016-01-21 |
CA2913781A1 (en) | 2014-12-24 |
CA2913781C (en) | 2022-05-10 |
EP3010506A1 (en) | 2016-04-27 |
DK3010506T3 (da) | 2021-07-12 |
JP2016523862A (ja) | 2016-08-12 |
US20140378508A1 (en) | 2014-12-25 |
MX2015017307A (es) | 2016-08-03 |
UA122999C2 (uk) | 2021-02-03 |
CL2015003690A1 (es) | 2016-10-28 |
TW201529069A (zh) | 2015-08-01 |
EP3010506B1 (en) | 2021-05-12 |
WO2014205229A1 (en) | 2014-12-24 |
IL242804B (en) | 2022-02-01 |
PE20170302A1 (es) | 2017-03-31 |
EP3010506A4 (en) | 2017-02-08 |
BR112015029918A2 (pt) | 2017-07-25 |
KR20160055122A (ko) | 2016-05-17 |
EA201690069A1 (ru) | 2016-06-30 |
KR102316933B1 (ko) | 2021-10-26 |
ES2879631T3 (es) | 2021-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
PE20150161A1 (es) | Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple | |
NI201100147A (es) | Métodos para tratar infartos agudos de miocardio y trastornos relacionados. | |
MX2022003072A (es) | Uso de pridopidina para el tratamiento de la disminucion funcional. | |
CO2018004776A2 (es) | Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana | |
EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
PE20142319A1 (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero | |
CL2011002858A1 (es) | Uso de una composicion farmaceutica transmucosa oral que comprende dexmedetomidina y una sal farmaceuticamente aceptable y un excipiente farmaceuticamente aceptable para preparar un medicamento util para tratar o prevenir el dolor. | |
DOP2016000254A (es) | Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso. | |
EA201270071A1 (ru) | Способ лечения пациента, нуждающегося в аспириновой терапии | |
MX2022015629A (es) | Uso de vibegron para tratar vejiga sobreactiva. | |
UY35890A (es) | Uso de laquinimod para retrasar la progresión de la enfermedad de huntington | |
AR099299A1 (es) | Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares | |
AR088845A1 (es) | Composiciones farmaceuticas que contienen 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetrahidro-quinolina para el tratamiento de las enfermedades y las afecciones de la piel | |
CO2018009543A2 (es) | Composición farmacéutica de liberación prolongada que comprende cisteamina o sal de la misma | |
AR074246A1 (es) | Derivados de 1-amino-alquilciclohexano para el tratamiento de trastornos del sueno | |
MX2021007324A (es) | Terapia oral con acido 6,8-bis-benciltio-octanoico. | |
DK2091520T3 (da) | Oral doseringsform omfattende trisubstituerede glycerol-forbindelser | |
AR076016A1 (es) | Domperidona a una dosis diaria baja para su uso en el tratamiento o la prevencion de una enfermedad asociada a una alteracion de la respuesta inmunitaria | |
AR104427A1 (es) | Composiciones farmacéuticas para terapia de combinación | |
AR096674A1 (es) | Método de tratamiento de un paciente humano que sufre de la enfermedad de huntington | |
EA201992690A1 (ru) | Применение вибегрона для лечения гиперактивного мочевого пузыря | |
EA201990553A1 (ru) | Применение придопидина для лечения ухудшения функциональной способности | |
CU20180036A7 (es) | Composiciones terapéuticas para el tratamiento del virus de la inmunodeficiencia humana | |
AR098924A1 (es) | Tratamiento de la esclerosis múltiple con una combinación de laquinimod y teriflunomida |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20211206 |